Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lan He

Showing results (691-700 of 704) with videos related to

Pageof 71
Sort By:
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology|October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 studyJinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy|March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority StudyHua Ye, Shengyun Liu, Jian Xu, et al.
Clinical and Experimental Rheumatology|September 6, 2018
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 studyLiqi Bi, Yuhui Li, Lan He, et al.
Frontiers in Medicine|April 3, 2026
Heterogeneous impact of tea consumption on COPD risk in smokers: insights from the PIFCOPD studyYijing Li, Jiping Liao, Ruiying Wang, et al.
Respiratory Research|May 25, 2023
Ambient fine particulate matter and allergic symptoms in the middle-aged and elderly population: results from the PIFCOPD studyShanshan Wei, Jiping Liao, Tao Xue, et al.
JAMA Network Open|March 14, 2025
Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical TrialZheyi Dong, Ping Luo, Shiren Sun, et al.
Annals of Translational Medicine|November 4, 2020
Development and formulation of the classification criteria for osteoarthritisCibo Huang, Zhiyi Zhang, Yaolong Chen, et al.
Annals of Translational Medicine|January 13, 2021
Erratum to development and formulation of the classification criteria for osteoarthritisCibo Huang, Zhiyi Zhang, Yaolong Chen, et al.
Pageof 71

Showing results (691-700 of 704) with videos related to

Sort By:
Pageof 71
Frontiers in Pharmacology|December 28, 2020
Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time PointsJinmei Su, Mengtao Li, Lan He, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2020
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical TrialJinmei Su, Mengtao Li, Lan He, et al.
Clinical Rheumatology|October 28, 2021
Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 studyJinmei Su, Mengtao Li, Lan He, et al.
Rheumatology and Therapy|March 25, 2023
Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority StudyHua Ye, Shengyun Liu, Jian Xu, et al.
Clinical and Experimental Rheumatology|September 6, 2018
Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 studyLiqi Bi, Yuhui Li, Lan He, et al.
Frontiers in Medicine|April 3, 2026
Heterogeneous impact of tea consumption on COPD risk in smokers: insights from the PIFCOPD studyYijing Li, Jiping Liao, Ruiying Wang, et al.
Respiratory Research|May 25, 2023
Ambient fine particulate matter and allergic symptoms in the middle-aged and elderly population: results from the PIFCOPD studyShanshan Wei, Jiping Liao, Tao Xue, et al.
JAMA Network Open|March 14, 2025
Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical TrialZheyi Dong, Ping Luo, Shiren Sun, et al.
Annals of Translational Medicine|November 4, 2020
Development and formulation of the classification criteria for osteoarthritisCibo Huang, Zhiyi Zhang, Yaolong Chen, et al.
Annals of Translational Medicine|January 13, 2021
Erratum to development and formulation of the classification criteria for osteoarthritisCibo Huang, Zhiyi Zhang, Yaolong Chen, et al.
Pageof 71